LUND, Sweden--(BUSINESS WIRE)--Regulatory News:
BioInvent International AB (publ) (OMXS:BINV)
· Enrolment of patients in the phase II GLACIER study with BI-204 (acute coronary syndrome) was completed in March. The first results are expected to be published in the third quarter.
· Treatment of all patients in BioInvent’s phase II study with TB-402 (thrombosis) was completed in the quarter. First results are expected to be published later in Q2.